Safety and efficacy of exenatide as monotherapy in drug naive patients with type 2 diabetes

Trial Profile

Safety and efficacy of exenatide as monotherapy in drug naive patients with type 2 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs Exenatide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Amylin Pharmaceuticals
  • Most Recent Events

    • 30 Oct 2009 According to a Amylin media release, Byetta has been approved by the US FDA as first-line treatment for type 2 diabetes mellitus.
    • 09 Jan 2008 Status changed from in progress to completed.
    • 06 Dec 2007 Positive results have been reported by Amylin.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top